TNP-ATP has become widely recognized as a potent and selective P2X receptor antagonist, and is currently being used to discriminate between subtypes of P2X receptors in a variety of tissues. We have investigated the ability of TNP-ATP to inhibit alpha,beta-methylene ATP (alpha,beta-meATP)-evoked responses in 1321N1 human astrocytoma cells expressing recombinant rat or human P2X(2/3) receptors. Pharmacological responses were measured using electrophysiological and calcium imaging techniques. TNP-ATP was a potent inhibitor of P2X(2/3) receptors, blocking both rat and human receptors with IC(50) values of 3 to 6 nM. In competition studies, 10 to 1000 microM alpha,beta-meATP was able to overcome TNP-ATP inhibition. Schild analysis revealed that TNP-ATP was a competitive antagonist with pA(2) values of -8.7 and -8.2. Inhibition of P2X(2/3) receptors by TNP-ATP was rapid in onset, reversible, and did not display use dependence. Although the onset kinetics of inhibition were concentration-dependent, the TNP-ATP off-kinetics were concentration-independent and relatively slow. Full recovery from TNP-ATP inhibition did not occur until >/=5 s after removal of the antagonist. Because of the slow off-kinetics of TNP-ATP, full competition with alpha,beta-meATP for receptor occupancy could be seen only after both ligands had reached a steady-state condition. It is proposed that the slowly desensitizing P2X(2/3) receptor allowed this competitive interaction to be observed over time, whereas the rapid desensitization of other P2X receptors (P2X(3)) may mask the detection of competitive inhibition by TNP-ATP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1124/mol.58.6.1502 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
P2X3 and P2X2/3 receptors inhibition produces a consistent analgesic efficacy: A systematic review and meta-analysis of preclinical studies.
Eur J Pharmacol
December 2024
Department of System's Biology, Medical School, University of Alcala, Alcalá de Henares, 28871, Madrid, Spain.
Article Synopsis
- P2X3 and P2X2/3 receptor inhibitors are being targeted for pain relief, and this study reviews preclinical data on their effectiveness.
- A meta-analysis of 67 articles revealed a significant overall pain reduction, particularly effective for visceral pain and mechanical hypersensitivity, with no notable differences based on sex or species.
- The route of administration mattered: systemic methods were more effective than intrathecal, while intracerebroventricular methods worsened pain; overall, further clinical research is needed to translate these findings into treatments.
Subtype-Specific Ligand Binding and Activation Gating in Homomeric and Heteromeric P2X Receptors.
Biomolecules
August 2024
Institute of Physiology II, Jena University Hospital, Friedrich Schiller University Jena, 07743 Jena, Germany.
Article Synopsis
- P2X receptors are important for sensory signaling and pain, functioning as cation channels activated by ATP, with their activation affected by Mg concentration and the binding of different ATP derivatives.
- New fluorescently labelled ATP derivatives allow researchers to study how these receptors respond differently to various ligands, highlighting unique behaviors among P2X2, P2X3, and P2X2/3 receptors.
- The research indicates that while magnesium influences P2X receptor activation, it still maintains strong binding, suggesting complex interactions that are critical for understanding the receptor's role in cellular signaling.
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men.
Br J Clin Pharmacol
August 2024
Hull York Medical School, University of Hull, Hull, UK.
Aims: We report on investigations exploring the P2X3-receptor antagonist filapixant's effect on taste perception and cough-reflex sensitivity and describe its pharmacokinetics, including its CYP3A4-interaction potential.
Methods: In a randomized, placebo-controlled, double-blind study, 3 × 12 healthy men (18-45 years) were assigned (3:1) to filapixant (20, 80 or 250 mg by mouth) or placebo twice daily over 2 weeks. A single dose of midazolam (1 mg), a CYP3A4 substrate, was administered with and without filapixant.
Druggable site near the upper vestibule determines the high affinity and P2X3 homotrimer selectivity of sivopixant/S-600918 and its analogue DDTPA.
Br J Pharmacol
April 2024
School of Sciences and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Background And Purpose: The P2X3 receptor, a trimeric ionotropic purinergic receptor, has emerged as a potential therapeutic target for refractory chronic cough (RCC). Nevertheless, gefapixant/AF-219, the only marketed P2X3 receptor antagonist, might lead taste disorders by modulating the human P2X2/3 (hP2X2/3) heterotrimer. Hence, in RCC drug development, compounds exhibiting strong affinity for the hP2X3 homotrimer and a weak affinity for the hP2X2/3 heterotrimer hold promise.
View Article and Find Full Text PDFTraditional Chinese medicine alleviating neuropathic pain targeting purinergic receptor P2 in purinergic signaling: A review.
Brain Res Bull
November 2023
Department of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address:
Past studies have suggested that Chinese herbal may alleviate neuropathic pain, and the mechanism might target the inhibition of purinergic receptor P2. This review discusses whether traditional Chinese medicine target P2 receptors in neuropathic pain and its mechanism in order to provide references for future clinical drug development. The related literatures were searched from Pubmed, Embase, Sinomed, and CNKI databases before June 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!